Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports

Carcinoembryonic antigen glypican-3 (GPC3) is expressed by >40% of ovarian clear cell carcinoma (CCC) and is a promising immunotherapeutic target. We previously reported the safety of and immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patient...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Suzuki, Shiro, Shibata, Kiyosumi, Kikkawa, Fumitaka, Nakatsura, Tetsuya
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2014
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185885/
https://ncbi.nlm.nih.gov/pubmed/24252799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27217
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller